Tower Semiconductor Reports Third Quarter 2025 Financial Results

Tower Semiconductor Reports Third Quarter 2025 Financial Results GlobeNewswire November 10, 2025 Guiding Fourth Quarter 2025 Revenue to be Record $440 Million, Citing Revenue Growth Across its Core Technologies Investing an additional $300 Million in SiPho and SiGe Capacity Growth and Next Generation Capabilities MIGDAL HAEMEK, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) — Tower Semiconductor

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 GlobeNewswire November 10, 2025 Study in uncontrolled Graves' disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing with potentially registrational studies in GD, myasthenia gravis (MG), chronic inflammatory

Kaspi.kz 3Q & 9M 2025 Financial Results

Kaspi.kz 3Q & 9M 2025 Financial Results GlobeNewswire November 10, 2025 ALMATY, Kazakhstan, Nov. 10, 2025 (GLOBE NEWSWIRE) — Joint Stock Company Kaspi.kz (“Kaspi.kz”, “we”) (Nasdaq:KSPI) which operates the Kaspi.kz and Kaspi Pay Super Apps in Kazakhstan and owns 66.35% of Hepsiburada in Turkiye, today published its unaudited consolidated IFRS financial results for the quarter

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Biomea Fusion to Participate at Jefferies London Healthcare Conference GlobeNewswire November 10, 2025 SAN CARLOS, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it is scheduled to participate in a fireside chat at the upcoming

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD–The Liver Meeting(R) 2025

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD–The Liver Meeting(R) 2025 GlobeNewswire November 10, 2025 A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digital pathology In a second poster, spatial computational histology relying on baseline fibrosis features

Surge Copper Highlights Strengthening Policy Environment for Critical Minerals Development in Canada

Surge Copper Highlights Strengthening Policy Environment for Critical Minerals Development in Canada Company welcomes measures in Budget 2025 and new infrastructure investments supporting Canada's Critical Minerals Strategy GlobeNewswire November 10, 2025 Vancouver, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) provides its

Plug Power to Generate Over $275 Million Through Monetization of Electricity Rights and Operational Efficiencies; Supports Major U.S. Data Center Build-Out

Plug Power to Generate Over $275 Million Through Monetization of Electricity Rights and Operational Efficiencies; Supports Major U.S. Data Center Build-Out GlobeNewswire November 10, 2025 LATHAM, N.Y., Nov. 10, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced that it expects to

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology GlobeNewswire November 10, 2025 LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

(NASDAQ:ROIV),(NasdaqGM:ROIVW), BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine

Scroll to Top